nephrogenic systemic fibrosis

(redirected from Nephrogenic fibrosing dermopathy)
Also found in: Acronyms, Wikipedia.

nephrogenic systemic fibrosis

A rare condition linked to gadolinium-based MRI contrast solutions—in particular Omniscan and OptiMARK, which have a linear non-ionic structure and more likely to release Gd3+ to tissue—characterised by fibrosis of skin, joints, eyes and internal organs, resulting in scleromyxedema/papular mucinosis-like histologic appearance, limitation of joint movement, kidney failure and, in extreme cases, systemic fibrosis affecting the lungs, heart and liver.
 
Prevention
Some protection may be provided by diethylene-triaminepentaacetic acid.
Mentioned in ?
References in periodicals archive ?
Nephrogenic fibrosing dermopathy with involvement of the dura mater.
Characteristics of nephrogenic fibrosing dermopathy case-patients and matched controls * from hospital A--St.
The FDA is asking health care professionals and patients to report possible cases of nephrogenic systemic fibrosis and nephrogenic fibrosing dermopathy through the MedWatch program by phone (800-FDA-1088) or by the Internet at www.
Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Currently, 175 cases have been reported to the International Center for Nephrogenic Fibrosing Dermopathy Research.
The mystery surrounding nephrogenic fibrosing dermopathy deepened recently with the largest reported series to date, involving 13 affected Michigan patients.
Scleromyxedema can produce a similar fibroblastic picture, but again, there is a key differentiation since patients with nephrogenic fibrosing dermopathy have no associated IgG-[lambda] paraprotein.
Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis is a devastating disease that causes fibrosis of the skin and connective tissues.
Skin biopsies were consistent with nephrogenic systemic fibrosis (NSF), which is also know as nephrogenic fibrosing dermopathy (NFD).
These techniques are available on all Toshiba MR systems and particularly important because gadolinium, the most common contrast agent used for MRA exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
Contrast-free imaging is particularly important because gadolinium, the most common contrast agent used for magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) exams, has been directly linked to a sometimes fatal disease that occurs in patients with renal insufficiency, called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermopathy (NFD).
The introduction of TRIMETASPHERE([R])-based contrast agents may help prevent the recently discovered disease, Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy (NSF/NFD), which has been attributed to current gadolinium-based contrast agents used in MRI procedures.